Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Chengdu Easton Biopharmaceuticals Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 4.95%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Chengdu Easton Biopharmaceuticals Co 3-Year ROIIC % Related Terms
Chengdu Easton Biopharmaceuticals Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co 3-Year ROIIC % Chart
SHSE:688513 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a 3-Year ROIIC % of 4.95 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 42% below median its historical median of 8.55. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #556 out of 1315 companies in the Biotechnology industry, placing it in the top 42.3%.
Is Chengdu Easton Biopharmaceuticals Co's 3-Year ROIIC % too high?
Chengdu Easton Biopharmaceuticals Co's current 3-Year ROIIC % of 4.95 is 42% below median its 10-year median of 8.55. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #556 out of 1315 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #556 out of 1315 companies for 3-Year ROIIC %. This puts Chengdu Easton Biopharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current 3-Year ROIIC % is 4.95, which is 42% below median its own 10-year median of 8.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥46.46, compared to a current price of ¥50.37 — trading 8.4% above its estimated fair value. The current 3-Year ROIIC % is 4.95, which is 42% below median its 10-year median of 8.55. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current 3-Year ROIIC % is 4.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥50.37 is trading 8.4% above its estimated GF Value™ of ¥46.46.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
3-Year ROIIC %: 4.95 (42% below median its 10-year median of 8.55)
GF Value™: ¥46.46 vs. price of ¥50.37 (8.4% above fair value)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score
Get the complete analysis for SHSE:688513
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
